𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Partial Response to Entecavir and Tenofovir in Naïve Patients with Chronic Hepatitis B: Clinical Relevance and Management

✍ Scribed by Pietro Lampertico, Mauro Viganò, Massimo Colombo

Book ID
113091696
Publisher
Current Science Inc.
Year
2012
Tongue
English
Weight
123 KB
Volume
11
Category
Article
ISSN
1540-3416

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Correlation of serum hepatitis B surface
Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B
✍ Myoung Hee Lee; Da Mi Lee; Soon Sun Kim; Jae Youn Cheong; Sung Won Cho 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 2 views

## Abstract Recent studies have suggested that quantifying the serum HBsAg levels can predict the response to pegylated interferon. We aimed to determine the change in serum HBsAg levels during entecavir (ETV) treatment and the correlation with treatment response in chronic HBeAg‐positive and HBeAg

Entecavir treatment for chronic hepatiti
Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response
✍ Roeland Zoutendijk; Jurriën G. P. Reijnders; Ashley Brown; Fabien Zoulim; David 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 315 KB 👁 1 views

Entecavir (ETV) is a potent inhibitor of viral replication in nucleos(t)ide analogue (NA)-naïve chronic hepatitis B (CHB) patients. The aim of this study was to investigate the long term efficacy and safety of ETV in NA-naïve CHB patients, particularly in those with detectable hepatitis B virus (HBV

Corrections: Entecavir treatment for chr
Corrections: Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response
📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB 👁 1 views

In the August 2011 issue of HEPATOLOGY, in the article entitled ''Carcinogen-induced hepatic tumors in KLF6þ/À mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation'' (volume 54, pages 522-531), Dr.